{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T14:32:34Z","timestamp":1790519554593,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,6,18]],"date-time":"2019-06-18T00:00:00Z","timestamp":1560816000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,6,18]],"date-time":"2019-06-18T00:00:00Z","timestamp":1560816000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"crossref","award":["2018R1C1B3004435"],"award-info":[{"award-number":["2018R1C1B3004435"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"crossref","award":["2014R1A5A2010008"],"award-info":[{"award-number":["2014R1A5A2010008"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1007\/s12072-019-09954-3","type":"journal-article","created":{"date-parts":[[2019,6,18]],"date-time":"2019-06-18T15:02:58Z","timestamp":1560870178000},"page":"490-500","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":73,"title":["Prognostic subclass of intrahepatic cholangiocarcinoma by integrative molecular\u2013clinical analysis and potential targeted approach"],"prefix":"10.1007","volume":"13","author":[{"given":"Keun Soo","family":"Ahn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu Na","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taofic","family":"Mounajjed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong Hoon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae-Seok","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre A.","family":"Kocher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loretta K.","family":"Allotey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitesh J.","family":"Borad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lewis R.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1385-8308","authenticated-orcid":false,"given":"Koo Jeong","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,18]]},"reference":[{"key":"9954_CR1","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.cld.2007.11.003","volume":"12","author":"BR Blechacz","year":"2008","unstructured":"Blechacz BR, Gores GJ. Cholangiocarcinoma. Clin Liver Dis 2008;12:131\u2013150, ix","journal-title":"Clin Liver Dis"},{"key":"9954_CR2","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1471-2407-2-10","volume":"2","author":"T Patel","year":"2002","unstructured":"Patel T. Worldwide trends in mortality from biliary tract malignancies. BMC Cancer 2002;2:10","journal-title":"BMC Cancer"},{"key":"9954_CR3","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1053\/j.gastro.2011.12.005","volume":"142","author":"JB Andersen","year":"2012","unstructured":"Andersen JB, Spee B, Blechacz BR, Avital I, Komuta M, Barbour A, et al. Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology 2012;142:1021\u20131031 e1015","journal-title":"Gastroenterology"},{"key":"9954_CR4","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1158\/2159-8290.CD-17-0368","volume":"7","author":"A Jusakul","year":"2017","unstructured":"Jusakul A, Cutcutache I, Yong CH, Lim JQ, Huang MN, Padmanabhan N, et al. Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma. Cancer Discov 2017;7:1116\u20131135","journal-title":"Cancer Discov"},{"key":"9954_CR5","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1053\/j.gastro.2013.01.001","volume":"144","author":"D Sia","year":"2013","unstructured":"Sia D, Hoshida Y, Villanueva A, Roayaie S, Ferrer J, Tabak B, et al. Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology 2013;144:829\u2013840","journal-title":"Gastroenterology"},{"key":"9954_CR6","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1016\/j.celrep.2017.02.033","volume":"18","author":"F Farshidfar","year":"2017","unstructured":"Farshidfar F, Zheng S, Gingras MC, Newton Y, Shih J, Robertson AG, et al. integrative genomic analysis of cholangiocarcinoma identifies distinct IDH-mutant molecular profiles. Cell Rep 2017;18:2780\u20132794","journal-title":"Cell Rep"},{"key":"9954_CR7","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1038\/modpathol.2013.241","volume":"27","author":"JY Liau","year":"2014","unstructured":"Liau JY, Tsai JH, Yuan RH, Chang CN, Lee HJ, Jeng YM. Morphological subclassification of intrahepatic cholangiocarcinoma: etiological, clinicopathological, and molecular features. Mod Pathol 2014;27:1163\u20131173","journal-title":"Mod Pathol"},{"key":"9954_CR8","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1038\/modpathol.2017.22","volume":"30","author":"M Akita","year":"2017","unstructured":"Akita M, Fujikura K, Ajiki T, Fukumoto T, Otani K, Azuma T, et al. Dichotomy in intrahepatic cholangiocarcinomas based on histologic similarities to hilar cholangiocarcinomas. Mod Pathol 2017;30:986\u2013997","journal-title":"Mod Pathol"},{"key":"9954_CR9","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1097\/FPC.0000000000000086","volume":"24","author":"ML Alvarellos","year":"2014","unstructured":"Alvarellos ML, Lamba J, Sangkuhl K, Thorn CF, Wang L, Klein DJ, et al. PharmGKB summary: gemcitabine pathway. Pharmacogenet Genom 2014;24:564\u2013574","journal-title":"Pharmacogenet Genom"},{"key":"9954_CR10","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1053\/jhep.2001.28233","volume":"34","author":"H Kuper","year":"2001","unstructured":"Kuper H, Ye W, Broome U, Romelsjo A, Mucci LA, Ekbom A, et al. The risk of liver and bile duct cancer in patients with chronic viral hepatitis, alcoholism, or cirrhosis. Hepatology 2001;34:714\u2013718","journal-title":"Hepatology"},{"key":"9954_CR11","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jhep.2008.10.019","volume":"50","author":"DL Zheng","year":"2009","unstructured":"Zheng DL, Zhang L, Cheng N, Xu X, Deng Q, Teng XM, et al. Epigenetic modification induced by hepatitis B virus X protein via interaction with de novo DNA methyltransferase DNMT3A. J Hepatol 2009;50:377\u2013387","journal-title":"J Hepatol"},{"key":"9954_CR12","first-page":"904","volume":"19","author":"HY Sun","year":"2011","unstructured":"Sun HY, Li Y, Guo K, Kang XN, Sun C, Liu YK. Identification of metastasis-related osteopontin expression and glycosylation in hepatocellular carcinoma. Zhonghua Gan Zang Bing Za Zhi 2011;19:904\u2013907","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"9954_CR13","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1634\/theoncologist.2011-0386","volume":"17","author":"DR Borger","year":"2012","unstructured":"Borger DR, Tanabe KK, Fan KC, Lopez HU, Fantin VR, Straley KS, et al. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist 2012;17:72\u201379","journal-title":"Oncologist"},{"key":"9954_CR14","doi-asserted-by":"publisher","first-page":"e115383","DOI":"10.1371\/journal.pone.0115383","volume":"9","author":"CR Churi","year":"2014","unstructured":"Churi CR, Shroff R, Wang Y, Rashid A, Kang HC, Weatherly J, et al. Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications. PLoS One 2014;9:e115383","journal-title":"PLoS One"},{"key":"9954_CR15","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1097\/MOG.0000000000000171","volume":"31","author":"MJ Borad","year":"2015","unstructured":"Borad MJ, Gores GJ, Roberts LR. Fibroblast growth factor receptor 2 fusions as a target for treating cholangiocarcinoma. Curr Opin Gastroenterol 2015;31:264\u2013268","journal-title":"Curr Opin Gastroenterol"},{"key":"9954_CR16","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1002\/jhbp.262","volume":"22","author":"S Maeda","year":"2015","unstructured":"Maeda S, Morikawa T, Takadate T, Suzuki T, Minowa T, Hanagata N, et al. Mass spectrometry-based proteomic analysis of formalin-fixed paraffin-embedded extrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Sci 2015;22:683\u2013691","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"9954_CR17","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1002\/hep.25595","volume":"55","author":"M Komuta","year":"2012","unstructured":"Komuta M, Govaere O, Vandecaveye V, Akiba J, Van Steenbergen W, Verslype C, et al. Histological diversity in cholangiocellular carcinoma reflects the different cholangiocyte phenotypes. Hepatology 2012;55:1876\u20131888","journal-title":"Hepatology"},{"key":"9954_CR18","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1093\/jnci\/djj498","volume":"98","author":"T Arumugam","year":"2006","unstructured":"Arumugam T, Ramachandran V, Logsdon CD. Effect of cromolyn on S100P interactions with RAGE and pancreatic cancer growth and invasion in mouse models. J Natl Cancer Inst 2006;98:1806\u20131818","journal-title":"J Natl Cancer Inst"},{"key":"9954_CR19","doi-asserted-by":"publisher","first-page":"7091","DOI":"10.1158\/0008-5472.CAN-11-1367","volume":"71","author":"L Dumartin","year":"2011","unstructured":"Dumartin L, Whiteman HJ, Weeks ME, Hariharan D, Dmitrovic B, Iacobuzio-Donahue CA, et al. AGR2 is a novel surface antigen that promotes the dissemination of pancreatic cancer cells through regulation of cathepsins B and D. Cancer Res 2011;71:7091\u20137102","journal-title":"Cancer Res"},{"key":"9954_CR20","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s10555-013-9444-6","volume":"32","author":"N Beauchemin","year":"2013","unstructured":"Beauchemin N, Arabzadeh A. Carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) in cancer progression and metastasis. Cancer Metastasis Rev 2013;32:643\u2013671","journal-title":"Cancer Metastasis Rev"},{"key":"9954_CR21","first-page":"1085","volume":"18","author":"J Akagi","year":"2001","unstructured":"Akagi J, Takai E, Tamori Y, Nakagawa K, Ogawa M. CA19-9 epitope a possible marker for MUC-1\/Y protein. Int J Oncol 2001;18:1085\u20131091","journal-title":"Int J Oncol"},{"key":"9954_CR22","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1476-4598-2-9","volume":"2","author":"J Ringel","year":"2003","unstructured":"Ringel J, Lohr M. The MUC gene family: their role in diagnosis and early detection of pancreatic cancer. Mol Cancer 2003;2:9","journal-title":"Mol Cancer"},{"key":"9954_CR23","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1080\/15384047.2017.1281499","volume":"18","author":"S Yang","year":"2017","unstructured":"Yang S, Che SP, Kurywchak P, Tavormina JL, Gansmo LB, Correa-de-Sampaio P, et al. Detection of mutant KRAS and TP53 DNA in circulating exosomes from healthy individuals and patients with pancreatic cancer. Cancer Biol Ther 2017;18:158\u2013165","journal-title":"Cancer Biol Ther"},{"key":"9954_CR24","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1158\/1078-0432.CCR-14-3296","volume":"22","author":"A Moeini","year":"2016","unstructured":"Moeini A, Sia D, Bardeesy N, Mazzaferro V, Llovet JM. Molecular pathogenesis and targeted therapies for intrahepatic cholangiocarcinoma. Clin Cancer Res 2016;22:291\u2013300","journal-title":"Clin Cancer Res"},{"key":"9954_CR25","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1172\/JCI66027","volume":"123","author":"C Kordes","year":"2013","unstructured":"Kordes C, Haussinger D. Hepatic stem cell niches. J Clin Invest 2013;123:1874\u20131880","journal-title":"J Clin Invest"},{"key":"9954_CR26","first-page":"272","volume":"2","author":"V Cardinale","year":"2013","unstructured":"Cardinale V, Bragazzi MC, Carpino G, Torrice A, Fraveto A, Gentile R, et al. Cholangiocarcinoma: increasing burden of classifications. Hepatobiliary Surg Nutr 2013;2:272\u2013280","journal-title":"Hepatobiliary Surg Nutr"},{"key":"9954_CR27","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1111\/jgh.13059","volume":"31","author":"BS Lee","year":"2016","unstructured":"Lee BS, Lee SH, Son JH, Jang DK, Chung KH, Paik WH, et al. Prognostic value of CA 19-9 kinetics during gemcitabine-based chemotherapy in patients with advanced cholangiocarcinoma. J Gastroenterol Hepatol 2016;31:493\u2013500","journal-title":"J Gastroenterol Hepatol"},{"key":"9954_CR28","doi-asserted-by":"publisher","first-page":"7811","DOI":"10.1158\/0008-5472.CAN-08-1320","volume":"68","author":"V Ramachandran","year":"2008","unstructured":"Ramachandran V, Arumugam T, Wang H, Logsdon CD. Anterior gradient 2 is expressed and secreted during the development of pancreatic cancer and promotes cancer cell survival. Cancer Res 2008;68:7811\u20137818","journal-title":"Cancer Res"},{"key":"9954_CR29","doi-asserted-by":"publisher","first-page":"e1004135","DOI":"10.1371\/journal.pgen.1004135","volume":"10","author":"MJ Borad","year":"2014","unstructured":"Borad MJ, Champion MD, Egan JB, Liang WS, Fonseca R, Bryce AH, et al. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. PLoS Genet 2014;10:e1004135","journal-title":"PLoS Genet"},{"key":"9954_CR30","first-page":"617","volume":"111","author":"J Yamamoto","year":"1992","unstructured":"Yamamoto J, Kosuge T, Takayama T, Shimada K, Makuuchi M, Yoshida J, et al. Surgical treatment of intrahepatic cholangiocarcinoma: four patients surviving more than five years. Surgery 1992;111:617\u2013622","journal-title":"Surgery"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-019-09954-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12072-019-09954-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-019-09954-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,16]],"date-time":"2020-06-16T23:28:02Z","timestamp":1592350082000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12072-019-09954-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,18]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["9954"],"URL":"https:\/\/doi.org\/10.1007\/s12072-019-09954-3","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,18]]},"assertion":[{"value":"6 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Keun Soo Ahn, Daniel O\u2019Brien, Yu Na Kang, Taofic Mounajjed<sup>4<\/sup>, Yong Hoon Kim, Tae-Seok Kim, Jean-Pierre A. Kocher, Loretta K. Allotey, Mitesh J. Borad, Lewis R. Roberts, and Koo Jeong Kang declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"RNA sequencing data of this manuscript is registered at Gene Expression Omnibus () with GEO accession number of GSE107943","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"This study was approved by institutional review boards at both institutions (Keimyung University Dongsan Medical Center: IRB No. 2014-12-066, Mayo clinic: IRB No. 16-007369) and included secondary use of human-derived materials.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent for the human-derived materials was obtained from all patients before surgery.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}